GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Price-to-Funds-From-Operations

Elicera Therapeutics AB (OSTO:ELIC) Price-to-Funds-From-Operations : (As of Jun. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Elicera Therapeutics AB (OSTO:ELIC) Business Description

Traded in Other Exchanges
Address
Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.